Completed PHASE1/PHASE2 INTERVENTIONAL 2-arm NCT02229071

Safety and Efficacy of Donafenib in Patients With Advanced Hepatocellular Carcinoma

Donafenib in Advanced Hepatocellular Carcinoma: A Randomized Phase 1B Study of Safety, Efficacy, and Pharmacokinetics

Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Conditions HCC

Interventions Donafenib(200mg) Donafenib(300mg)

Updated 6 times since 2017 Last updated: Mar 20, 2019 Started: Apr 30, 2014 Primary completion: Dec 31, 2015 Completion: Oct 30, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02229071, this PHASE1/PHASE2 trial focuses on HCC and remains completed. Sponsored by Suzhou Zelgen Biopharmaceuticals Co.,Ltd, it has been updated 6 times since 2014, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1_PHASE2
Apr 2019 — Jan 2021 [monthly]

Completed PHASE1_PHASE2
Jun 2018 — Apr 2019 [monthly]

Completed PHASE1_PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE1_PHASE2

First recorded

Apr 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Tigermed Consulting Co., Ltd

Data source: Suzhou Zelgen Biopharmaceuticals Co.,Ltd

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Chengdu, China